Cancer Research

Melanoma, an aggressive form of skin cancer, has been increasing in incidence in adults over the past 40 years.

Pediatric melanoma is rare (5 or 6 children per million) but some studies indicate that incidence has been increasing. A new study in The Journal of Pediatrics found that is not so, and the incidence of pediatric melanoma in the United States decreased from 2004-2010.

On one side of the political spectrum in America and across a broader swath of Europe, science is controversial - especially genetic engineering. But genetic engineering has been done since humans first deduced they could shape the natural world, if anything it has gotten precise in a way that was never possible before.

Now it mean even help fight against cancer - and it may do so using Salmonella, more famous as a bacteria that lives in intestines.

A vital self-destruct switch in cells is hijacked - making some pancreatic and non small cell lung cancers more aggressive, according to new research which found that mutations in the KRAS gene interferes with protective self-destruct switches, known as TRAIL receptors, which usually help to kill potentially cancerous cells.

The research, carried out in cancer cells and mice, shows that in cancers with faulty versions of the KRAS gene these TRAIL receptors actually help the cancer cells to grow and spread to new areas in the body. These KRAS faults occur in 95 percent of pancreatic cancers - pancreatic ductal adenocarcinoma - and 30 percent of non small cell lung cancers.

Melanoma is the leading cause of skin cancer¬related deaths and surgical excision is the primary therapy for melanoma. It is recommended that melanomas should be excised within 4 to 6 weeks of the diagnostic biopsy because surgical delay may result in the potential for increased illness and death from other malignant neoplasms, along with anxiety and stress. 

In a study that included more than 32,000 cases of melanoma among Medicare patients, approximately 20 percent experienced a delay of surgery that was longer than 1.5 months, and about 8 percent of patients waited longer than 3 months for surgery.

Cancer researchers have identified a key signaling pathway in B-cell lymphoma, a malignant type of blood cancer. They demonstrate that the signaling pathway can be blocked using compounds that are already in clinical development.

Scientists have identified a small RNA molecule named miR-182 that can suppress cancer-causing genes in mice with glioblastoma mulitforme (GBM), a deadly and incurable type of brain tumor. 
There are 16,000 new cases of the deadly brain tumor reported in the U.S. every year. Patients have a very poor prognosis, with median survival of just 14 to 16 months.

Standard chemotherapy drugs stop cancer cells from reproducing by damaging DNA but the new method instead stops the source that creates those cancer cells: genes that are overexpressing certain proteins.

A new study finds that many women diagnosed with breast cancer are concerned about a genetic predisposition for developing other cancers and the chances of a loved one developing cancer.

America has expensive health care but it also has the best health care. As the Federal government has discovered in trying to implement the Affordable Care Act, giving something away for free will not maintain that level of quality.

Instead, the future could be one where there are two classes of care - those with private insurance and those without. Higher treatment costs are already linked to better survival rates, according to a study by Yale School of Medicine researchers in the Cancer Outcomes Public Policy and Effectiveness Research (COPPER) Center at Yale School of Medicine and Yale Cancer Center.  
A prostate cancer test using gold nanoparticles costs less than a $1 and yields results in minutes - results show it to be more sensitive and more exact than the current standard test for early-stage prostate cancer, the less precise PSA test that's now used. 
Stage IV cancer patients and their caregivers don't agree on the value of another year of life versus other end-of-life improvements.

Cancer is an expensive proposition emotionally and also financially. High-cost treatments may result in only moderate improvements in length or quality of life. Because such decisions are very difficult for patients to make, in some cases the decision is entirely deferred to a family caregiver.